Bicocca Open Archive

Logo unimib boa
FONTANA, DILETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.890
AS - Asia 4.745
EU - Europa 3.750
SA - Sud America 755
AF - Africa 125
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 7
Totale 15.302
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.695
SG - Singapore 1.493
IT - Italia 1.175
CN - Cina 957
VN - Vietnam 923
DE - Germania 632
HK - Hong Kong 561
BR - Brasile 558
RU - Federazione Russa 516
IE - Irlanda 277
SE - Svezia 261
GB - Regno Unito 189
FR - Francia 176
IN - India 136
CA - Canada 121
KR - Corea 100
FI - Finlandia 99
ID - Indonesia 98
BD - Bangladesh 87
AR - Argentina 79
IQ - Iraq 78
UA - Ucraina 74
ES - Italia 73
TR - Turchia 73
PL - Polonia 54
JP - Giappone 47
MX - Messico 43
AT - Austria 41
NL - Olanda 41
ZA - Sudafrica 41
CH - Svizzera 37
PK - Pakistan 35
EC - Ecuador 29
SA - Arabia Saudita 25
BE - Belgio 22
PH - Filippine 22
AU - Australia 21
DK - Danimarca 21
UZ - Uzbekistan 21
VE - Venezuela 21
PE - Perù 20
CO - Colombia 18
MA - Marocco 18
CZ - Repubblica Ceca 17
EG - Egitto 13
LT - Lituania 13
IR - Iran 12
TN - Tunisia 11
KE - Kenya 10
UY - Uruguay 10
ET - Etiopia 9
PY - Paraguay 9
AZ - Azerbaigian 8
CL - Cile 8
NP - Nepal 7
NZ - Nuova Zelanda 7
DO - Repubblica Dominicana 6
JO - Giordania 6
KG - Kirghizistan 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
EU - Europa 5
NI - Nicaragua 5
NO - Norvegia 5
CR - Costa Rica 4
DZ - Algeria 4
IL - Israele 4
LY - Libia 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
RO - Romania 4
AL - Albania 3
AM - Armenia 3
BG - Bulgaria 3
BM - Bermuda 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CI - Costa d'Avorio 3
GR - Grecia 3
KZ - Kazakistan 3
MU - Mauritius 3
PT - Portogallo 3
TH - Thailandia 3
CY - Cipro 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MM - Myanmar 2
MT - Malta 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
Totale 15.282
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.055
Singapore 841
Ashburn 616
San Jose 555
Hong Kong 534
Milan 441
Frankfurt am Main 413
Ho Chi Minh City 288
Dublin 274
Hanoi 225
Chandler 224
Dallas 203
Los Angeles 191
Wilmington 172
Fairfield 167
New York 164
Beijing 156
Hefei 152
Houston 137
Santa Clara 116
The Dalles 108
Chicago 93
Dearborn 91
Seoul 90
Munich 84
Woodbridge 84
Jakarta 71
Seattle 69
São Paulo 66
Shanghai 63
Toronto 58
Lauterbourg 56
Princeton 56
Helsinki 53
Buffalo 47
Moscow 46
Cambridge 45
Council Bluffs 42
Da Nang 42
Jacksonville 41
Orem 38
Warsaw 37
Kent 36
Nuremberg 33
Boyds 31
Altamura 30
Guangzhou 29
London 29
Nanjing 29
Tokyo 29
Haiphong 28
Johannesburg 28
Zurich 28
Lawrence 26
Chennai 25
Kirkuk 25
Baghdad 24
Biên Hòa 23
Turku 23
Vienna 23
Hải Dương 22
Montreal 22
Monza 22
Poplar 22
Dong Ket 21
Sesto San Giovanni 20
Atlanta 19
Denver 19
Boardman 18
Desio 18
Rio de Janeiro 18
Romola 18
Stockholm 18
Tashkent 18
Rome 17
Brussels 16
Phoenix 16
Tianjin 16
Amsterdam 15
Ha Long 15
Kocaeli 15
Lima 15
Pavia 15
Turin 15
Belo Horizonte 14
Carate Brianza 14
Genoa 14
Istanbul 14
Paris 14
San Diego 14
Ankara 13
Lappeenranta 13
Salt Lake City 13
Boston 12
Lissone 12
Meda 12
Ottawa 12
Pune 12
Riyadh 12
Düsseldorf 11
Totale 9.439
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 602
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 454
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia 453
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 446
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 444
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 440
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 434
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 412
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 404
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 377
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 372
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 371
Idiopathic erythrocytosis: a germline disease? 369
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 364
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 360
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 342
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 342
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 316
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 310
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 300
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 297
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 294
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 282
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 279
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 277
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 273
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 266
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 255
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 252
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 250
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 247
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 240
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 238
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 232
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 231
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 226
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 216
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 214
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 211
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 211
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage 207
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 191
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 189
Role of somatic ETNK1 mutation in the mitochondrial activity 188
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 186
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape 185
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 183
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 182
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 173
Integrating mutational profiles and single-cell transcriptional data using LASSO regularized regression to elucidate key molecular functions involved in the pathogenesis of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with neutrophilia 172
ETNK1 mutations increase mitochondrial activity and promote DNA damage through ROS production 162
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia 154
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 146
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 146
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 136
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia 124
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer 98
Totale 15.725
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.586
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.586
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021235 0 0 0 0 0 0 0 0 0 0 124 111
2021/2022651 84 88 79 61 36 59 21 20 30 43 56 74
2022/20231.152 108 271 124 104 110 152 18 62 64 34 32 73
2023/20241.216 46 43 64 76 122 276 235 36 105 52 51 110
2024/20253.188 149 284 170 172 254 120 222 114 334 576 285 508
2025/20267.008 1.169 544 612 880 704 342 1.118 299 514 671 155 0
Totale 15.725